David Kaysen is stepping down from Sun BioPharma after three years in the president and CEO office, handing the reins to executive chairman and founder Michael Cullen. His departure is nothing against him, the company notes, but a result of “the need for cost reductions to focus further spending on the current Phase 1a/1b clinical trial in the front-line combination study of SBP-101 with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer.”
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today provided a business update.
Synergy's been trying to sell itself for more than three years, but no buyer's willing to pay enough, the company admitted Thursday. Even worse? With its Trulance launch on the skids, Synergy's running out of money. If it can’t renegotiate terms with its lender, bankruptcy could be next.
Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble
Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market—and to add blockbuster sales to a portfolio that’s at the heart of Takeda’s $62 billion buyout.
Luoxin will lead clinical development in China and be responsible for all activities and expenses relating to clinical development, regulatory approval, and commercialization in China.
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome